Roundhill Glp-1 & Weight Loss ETF (OZEM)

$26.58 +0.08 (0.30%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 14,604
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:58 AM
$OZEM RSI: 52.75, MACD: 0.7358 Vol: 0.74, MA20: 34.03, MA50: 31.83 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 12:30 PM
$NVO's oral obesity pill just got FDA approval — a game changer in weight-loss drugs! 💊 🌟 First FDA-approved oral GLP-1 pill for chronic weight management in the U.S. 💰 Priced at $149/month, more accessible than injectables 📈 Participants lost 16.6% body weight in trials Discover why $OZEM, $THNR, and $PPH might be the smarter play here 👉 https://www.zacks.com/stock/news/2809629/the-obesity-pill-rush-healthcare-etfs-to-gain-as-fda-nods-to-novo-drug?cid=sm-stocktwits-2-2809629-body-26689&ADID=SYND_STOCKTWITS_TWEET_2_2809629_BODY_26689
0 · Reply
Ducklings
Ducklings Dec. 30 at 10:59 AM
$OZEM I really thought this had something to do with ozempic lol
0 · Reply
Europlus
Europlus Dec. 30 at 9:40 AM
$AMGN $LLY $NVO $OZEM What the fuck he is Talking about.
1 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:33 AM
$AMGN $LLY $NVO $OZEM What started with a focus on the drug’s ability to manage weight and combat related conditions such as heart disease, is now expanding further with growing interest in how it might also impact the brain.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:33 AM
$AMGN $LLY $NVO $OZEM Scientists, however, say that Novo’s medicine still has potential.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:32 AM
$AMGN $LLY $NVO $OZEM Novo Nordisk has had a difficult year as investors questioned the company’s ability to translate its strides in pioneering GLP-1 drugs to financial gains.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:32 AM
$AMGN $LLY $NVO $OZEM Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:26 AM
$AMGN $LLY $NVO $OZEM The stock’s ( $NVO) -to-date drop of 50% is being driven by increased competition from U.S. rival Eli Lilly and so-called compounding pharmacies making cheaper, copycat versions of semaglutide. A failure to convince investors that its pipeline will bring significant financial gains amid a flurry of hopeful market entrants also adds to the pressure.
0 · Reply
BloomBard
BloomBard Dec. 27 at 10:13 AM
$OZEM Positioning is increasingly shaped by how predictably management executes. Execution risk remains the main variable to watch. Evidence of repeatability could meaningfully alter perception. Future returns depend more on reliability than ambition.
0 · Reply
Latest News on OZEM
New Year, New Strategy: Navigating Weight Loss ETFs

Jan 12, 2026, 3:14 PM EST - 2 days ago

New Year, New Strategy: Navigating Weight Loss ETFs

HRTS THNR

Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch

Sep 12, 2024, 2:51 PM EDT - 1 year ago

Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch

CHAT MAGS

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Jun 24, 2024, 7:35 PM EDT - 1 year ago

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

THNR

OZEM: Investing in the Weight Loss Craze

May 29, 2024, 12:01 PM EDT - 1 year ago

OZEM: Investing in the Weight Loss Craze

This new weight loss drug ETF bets big on two of the industry's leading players

May 27, 2024, 12:01 PM EDT - 1 year ago

This new weight loss drug ETF bets big on two of the industry's leading players

New funds jump on weight loss trade

May 21, 2024, 5:02 PM EDT - 1 year ago

New funds jump on weight loss trade

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

May 21, 2024, 9:00 AM EDT - 1 year ago

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

Roundhill to launch active weight loss ETF

May 20, 2024, 1:40 PM EDT - 1 year ago

Roundhill to launch active weight loss ETF

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:58 AM
$OZEM RSI: 52.75, MACD: 0.7358 Vol: 0.74, MA20: 34.03, MA50: 31.83 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 12:30 PM
$NVO's oral obesity pill just got FDA approval — a game changer in weight-loss drugs! 💊 🌟 First FDA-approved oral GLP-1 pill for chronic weight management in the U.S. 💰 Priced at $149/month, more accessible than injectables 📈 Participants lost 16.6% body weight in trials Discover why $OZEM, $THNR, and $PPH might be the smarter play here 👉 https://www.zacks.com/stock/news/2809629/the-obesity-pill-rush-healthcare-etfs-to-gain-as-fda-nods-to-novo-drug?cid=sm-stocktwits-2-2809629-body-26689&ADID=SYND_STOCKTWITS_TWEET_2_2809629_BODY_26689
0 · Reply
Ducklings
Ducklings Dec. 30 at 10:59 AM
$OZEM I really thought this had something to do with ozempic lol
0 · Reply
Europlus
Europlus Dec. 30 at 9:40 AM
$AMGN $LLY $NVO $OZEM What the fuck he is Talking about.
1 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:33 AM
$AMGN $LLY $NVO $OZEM What started with a focus on the drug’s ability to manage weight and combat related conditions such as heart disease, is now expanding further with growing interest in how it might also impact the brain.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:33 AM
$AMGN $LLY $NVO $OZEM Scientists, however, say that Novo’s medicine still has potential.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:32 AM
$AMGN $LLY $NVO $OZEM Novo Nordisk has had a difficult year as investors questioned the company’s ability to translate its strides in pioneering GLP-1 drugs to financial gains.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:32 AM
$AMGN $LLY $NVO $OZEM Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 30 at 9:26 AM
$AMGN $LLY $NVO $OZEM The stock’s ( $NVO) -to-date drop of 50% is being driven by increased competition from U.S. rival Eli Lilly and so-called compounding pharmacies making cheaper, copycat versions of semaglutide. A failure to convince investors that its pipeline will bring significant financial gains amid a flurry of hopeful market entrants also adds to the pressure.
0 · Reply
BloomBard
BloomBard Dec. 27 at 10:13 AM
$OZEM Positioning is increasingly shaped by how predictably management executes. Execution risk remains the main variable to watch. Evidence of repeatability could meaningfully alter perception. Future returns depend more on reliability than ambition.
0 · Reply
inspector_gadget86
inspector_gadget86 Oct. 10 at 4:43 PM
$AMGN $LLY $NVO $OZEM Ozempic and similar drugs could interfere with common medical procedure
1 · Reply
inspector_gadget86
inspector_gadget86 Sep. 29 at 7:54 PM
$JAVA $LLY $NVO $OZEM Weight-loss drugs now linked to cancer protection in women, major new study reveals
0 · Reply
inspector_gadget86
inspector_gadget86 Sep. 29 at 12:41 PM
$OZEM $LLY $NVO $JAVA weight loss prescription growth in the U.S. would slow down amid competitive pressures.
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 29 at 9:28 AM
Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today $NVO $OZEM $JAVA https://stocktwits.com/news/equity/markets/why-wegovy-maker-novo-nordisk-s-stock-is-sliding-3-premarket-today/chDMDwYR37q
0 · Reply
TechForz
TechForz Sep. 23 at 2:51 PM
$QTUM any young investor not having this ETF along with $XME , $NUKZ and $OZEM are missing out big in the furure. BUY NOW!
0 · Reply
ShillsInShamble
ShillsInShamble Sep. 2 at 12:00 PM
$BINI $OZEM $NVDD $XPON $SNOA
0 · Reply
PaulLaurent
PaulLaurent Aug. 28 at 8:41 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $BINI $OZEM $NVDD $XPON $SNOA
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 11:18 AM
$NVO just scored a historic FDA win ✅ Wegovy is now the first GLP-1 approved for MASH, sending shares up 5% and opening the door beyond obesity & diabetes. 📈 ETFs loaded with NVO like $OZEM, $THNR, and $PPH stand to gain. See the full ETF impact here 👉 https://www.zacks.com/stock/news/2734231/nvo-wins-fda-approval-for-mash-treatment-etfs-likely-to-gain?cid=sm-stocktwits-2-2734231-teaser-8260&ADID=SYND_STOCKTWITS_TWEET_2_2734231_TEASER_8260
1 · Reply
TalkMarkets
TalkMarkets Aug. 9 at 6:40 PM
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data $LLY $IHE $PPH $MEDX $OZEM https://talkmarkets.com/content/etfs/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?post=514413&userid=123969
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 2:21 PM
$LLY plunges 14% on disappointing weight-loss pill data despite crushing Q2 earnings! 📉 Eli Lilly beat both top and bottom line estimates, with a 61% EPS jump and a 38% revenue surge. Yet, disappointing weight-loss pill data overshadowed its strong performance and raised FY outlook. Is this a buying opportunity? Check the ETFs like $IHE, $PPH, $OZEM with big LLY exposure here 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-body-6878&ADID=SYND_STOCKTWITS_TWEET_2_2684363_BODY_6878
0 · Reply
TechForz
TechForz Jun. 16 at 1:15 PM
$QTUM this with $NUKZ are going to be the darlings for medium to long term. Wish $OZEM matches it!
1 · Reply
Stock_Australopithecus
Stock_Australopithecus Jun. 10 at 4:20 PM
$OZEM $ALT $VKTX $TERN Ozem is up almost 5% and that thing barely moves at all even on solid green days (even the day the Nasdaq went up 12% it only went up 6%). Hard to explain what's happening here. Maybe there's acquisition rumors out there but no one knows precisely who the target is?
0 · Reply